

DAFTAR PUSTAKA

- AlQur'an dan Terjemahannya. 2011. Departemen Agama RI. Bandung: PT. Sygma Examedia Arkanlee.
- Abbas, A. K., Lichtman, A. H., & Pillai, S. 2014. Effector Mechanism of Humoral Immunity. *Basic immunology: functions and disorders of the immune system*. 4th edition. Elsevier Health Sciences. pp. 160-168
- Abdullah, M. 2000. *Doa sebagai Penyembuh untuk Mengatasi Stres, Frustrasi, Krisis, dan lain-lain*. Bandung: Al-Bayan. pp 65-75.
- Achmadi, 2010. *Manajemen Demam Berdarah Berbasis Wilayah*. Buletin Jendela Epidemiologi Demam Berdarah, Vol. 2. pp. 15-20.
- Amin, H.Z. & Sungkar, S. 2014. Perkembangan Mutakhir Vaksin Demam Berdarah Dengue. *eJournal Kedokteran Indonesia*. 1(3): 226-233.
- Arif, S. 2016. Hukum Membunuh Cicak, Semut, Tikus dan Nyamuk. <http://hukum-islam.net/hukum-membunuh-cicak-semut-tikus-dan-nyamuk-berpahala/>. Diakses tanggal 24 Februari 2017.
- Bahraen, R. 2011. Pro Kontra Hukum Imunisasi dan Vaksinasi. <https://muslim.or.id/7073-pro-kontra-hukum-imunisasi-dan-vaksinasi.html>. Diakses 27 Februari 2017.
- Balas, C., Kennel, A., Deauvieu, F., *et al.* 2011. Different Innate Signatures Induced in Human Monocyte-derived Dendritic Cells by Wild-type Dengue 3 Virus, Attenuated but Reactogenic Dengue 3 Vaccine Virus, or Attenuated Nonreactogenic Dengue 1-4 Vaccine Virus Strains. *Journal of Infectious Diseases*. 203(1): 103-108.
- Balmaseda, A., Hammond, S.N., Perez, L., *et al.* 2006. Serotypespecific Differences in Clinical Manifestations of Dengue. *Am J Trop Med Hyg*. 74(3): 449-56.
- Bhamarapravati, N. & Sutee, Y. 2000. Live Attenuated Tetravalent Dengue Vaccine. *Vaccine*. (18): 44-47.

- Beckett, C. G., Tjaden, J., Burgess, T., *et al.* 2011. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. *Vaccine*. 29(5): 960-968.
- Brooks, G. F., Butel, J. S., & Morse, S. A. 2013. Dengue. *Medical Microbiology*. Edisi 26. United States: The McGraw-Hill Companies, Inc. pp. 564-566.
- Cahyani, A.I. 2014. Teori dan Aplikasi Maqashid Al-Syari'ah. *Jurnal al-Qadau*. 1(2): 19-29.
- Capeding, M. R., Tran, N. H., Hadinegoro, S. R. S., *et al.* 2014. Clinical Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children in Asia: A Phase 3, Randomised, Observer-masked, Placebo-controlled Trial. *The Lancet*. 384(9951): 1358-1365.
- Centers for Disease Control and Prevention (CDC). 2014. Dengue Epidemiology. Centers for Disease Control and Prevention National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) Division of Vector-Borne Diseases (DVBD), USA. <https://www.cdc.gov/dengue/epidemiology/index.html>. Diakses tanggal 14 April 2017.
- Coller, B. A. G., Clements, D. E., Bett, A. J., *et al.* 2011. The Development of Recombinant Subunit Envelope-based Vaccines to Protect Against Dengue Virus Induced Disease. *Vaccine*. 29(42): 7267-7275.
- Departemen Kesehatan Republik Indonesia. 2000. Buletin DBD. <http://www.depkes.go.id/download.php?file=download/pusdatin/buletin/buletin-dbd.pdf>. Diakses tanggal 5 Februari 2017.
- Departemen Kesehatan Republik Indonesia. 2009. *Jendela Data dan Informasi Kesehatan*. Jakarta: Kementerian Kesehatan Republik Indonesia. pp. 3-12.
- Departemen Kesehatan Republik Indonesia. 2016. Wilayah KLB DBD Ada di 11 Kabupaten/Kota. <http://www.depkes.go.id/article/view/16020900001/wilayah-klb-dbd-ada-di-11-kabupaten-kota.html>. Diakses tanggal 2 Februari 2017.
- Dorland, W. 2006. *Kamus Kedokteran Dorland*. Edisi 25. Jakarta: EGC Medical Publisher. pp 276.
- Durbin, AP. & Whitehead, SS. 2010. Dengue Vaccine Candidates in Development. *Dengue Virus*. Berlin: Springer Berlin Heidelberg. pp. 129-143.

- Gallina, N.M.F. 2015. Process for Preparing an Attenuated Tetravalent Dengue Vaccine. U.S. Patent Application No. 14/847,422.
- Grabenstein, J. D. 2006. Facts & Comparisons. *ImmunoFacts: Vaccines and Immunologic Drugs*. (76): 372-380.
- Guy, B., Barrere, B., Malinowski, C., *et al.* 2011. From Research to Phase III: Preclinical, Industrial and Clinical Development of the Sanofi Pasteur Tetravalent Dengue Vaccine. *Vaccine*. 29(42): 7229-7241.
- Hassan. 2004. Imunisasi Dalam Pengobatan. <http://www.erasuslim.com/ks/um/42/9291>. Diakses tanggal 25 Februari 2017.
- Hadinegoro S.R.H. 2004. *Tatalaksana Demam Berdarah Dengue di Indonesia Departemen Kesehatan Republik Indonesia*. Edisi 3. Jakarta: Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan Lingkungan. pp 1-43.
- Holman, D. H., Wang, D., Raviprakash, K., *et al.* 2007. Two Complex, Adenovirus-based Vaccines that Together Induce Immune Responses to all Four Dengue Virus Serotypes. *Clinical and Vaccine Immunology*. 14(2): 182-189.
- Jackson, N., Boaz, M., Hu, B., *et al.* 2014. Abstract 576: Investigations of the Observed Efficacy of the CYD Tetravalent Dengue Vaccine in the Phase 2b Trial in Ratchaburi, Thailand. *The American Journal of Tropical Medicine and Hygiene*. (91): 172.
- Kanesa-Thanan, N., Sun, W., Kim-Ahn, G., *et al.* 2001. Safety and Immunogenicity of Attenuated Dengue Virus Vaccines (Aventis Pasteur) in Human Volunteers. *Vaccine*. 19(23): 3179-3188.
- Karyanti M.R. & Hadinegoro S.R.H. 2009. Perubahan Epidemiologi Demam Berdarah Dengue di Indonesia. *Sari Pediatri, Vol. 10, No. 6*. Jakarta: Departemen Ilmu Kesehatan Anak Rumah Sakit Dr. Cipto Mangunkusumo FKUI. pp. 12-14.
- Khetarpal, N. & Khanna, I. 2016. Dengue Fever: Causes, Complications, and Vaccine Strategies. *Journal of immunology research*. (2016): 1-14.

- Konishi E., Kosugi S., Imoto J. 2006. Dengue Tetravalent DNA Vaccine Inducing Neutralizing Antibody and Anamnestic Responses to Four Serotypes in Mice. *Vaccine*. 24(12): 2200-2207.
- Kumaria, R. 2010. Correlation of Disease Spectrum among Four Dengue Serotypes: A Five Years Hospital Based Study from India. *Brazilian Journal of Infectious Diseases*. 14(2): 141-146.
- Kurane, I. 2007. Dengue Hemorrhagic Fever with Special Emphasis on Immunopathogenesis. *Comparative immunology, microbiology and infectious diseases*. 30(5): 329-340.
- Kurniati, D. 2013. Kemenkes: Indonesia Masih Endemis Demam Berdarah. <https://nasional.tempo.co/read/news/2013/07/26/173500085/kemenkes-indonesia-masih-endemis-demam-berdarah>. Diakses: 23 Maret 2017.
- Lidenbach B.D., Thiel H.J., Rice C.M. 2007. Flaviviridae: The Viruses and Their Replication. *Fields Virology Fifth Edition*. Boston: Lippincott Williams & Wilkins. pp. 1101-1151.
- Mudd, P.A., Piaskowski, S.M., Neves, P.C.C., *et al.* 2010. The Live-attenuated Yellow Fever Vaccine 17D Induces Broad and Potent T-cell Responses Against Several Viral Proteins in Indian Rhesus Macaques—Implications for Recombinant Vaccine Design. *Immunogenetics*. 62(9): 593-600.
- NIAID (National Institute of Allergy and Infectious Disease). 2012. Vaccines. <https://www.niaid.nih.gov/research/vaccines>. Diakses tanggal 28 April 2017.
- Noisakran, S. & Perng, G.C. 2008. Alternate Hypothesis on the Pathogenesis of Dengue Hemorrhagic Fever (DHF)/Dengue Shock Syndrome (DSS) in Dengue Virus Infection. *Experimental Biology and Medicine*. 233(4): 401-408.
- Nuryusmansyah, R. 2013. Dalam Kondisi Darurat Hal Yang Terlarang Dbolehkan. <https://muslim.or.id/19369-dalam-kondisi-darurat-hal-yang-terlarang-dibolehkan.html>. Diakses tanggal 13 April 2017.
- Osorio, J. E., Huang, C. Y. H., Kinney, R. M., *et al.* 2011. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. *Vaccine*. 29(42): 7251-7260.

- Putnak, J.R., Collier, B.A., Voss, G., *et al.* 2005. An Evaluation of Dengue Type-2 Inactivated, Recombinant Subunit, and Live-attenuated Vaccine Candidates in the Rhesus Macaque Model. *Vaccine*. 23(35): 4442-4452.
- Ranuh, I.G.N. 2008. *Pedoman Imunisasi di Indonesia*. Edisi 3. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia. pp. 52-57.
- Raviprakash, K., Defang, G., Burgess, T., *et al.* 2009. Advances in Dengue Vaccine Development. *Human Vaccines*. 5(8): 520-528.
- Rothman, A.L. 2004. Dengue: Defining Protective Versus Pathologic Immunity. *The Journal of Clinical Investigation*. 113(7): 946-951.
- Sabchareon, A., Wallace, D., Sirivichayakul, C., *et al.* 2012. Protective Efficacy of the Recombinant, Live-attenuated, CYD Tetravalent Dengue Vaccine in Thai Schoolchildren: A Randomised, Controlled Phase 2b Trial. *The Lancet*. 380(9853): 1559-1567.
- Sahaly, B. 2010. Pencegahan Penyakit dalam Tinjauan Islam. <http://bintusahaly.com/2010/12/pencegahan-penyakit-dalam-tinjauan.html>. Diakses 20 April 2017.
- Saifuddin, 2016. Al-Baqarah:26-27 (Nyamuk sebagai Perumpamaan yang menarik Perhatian). <http://saifuddinasm.com/2013/11/13/al-baqarah26-27-nyamuk-sebagai-perumpamaan-yang-menarik-perhatian/>. Diakses 30 Maret 2017.
- Scaturro, P., Cortese, M., Chatel-Chaix, L., *et al.* 2015. Dengue Virus Non-structural Protein 1 Modulates Infectious Particle Production via Interaction with the Structural Proteins. *PLoS Pathogens*. 11(11): e1005277.
- SEARO (South East Asia Regional Office of WHO). 2011. *Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Hemorrhagic Fever, Revised and Expanded Edition*. India: World Health Organization, Regional Office for South-East Asia. pp. 17-28.
- Setiati T.E., Wagenaar J.F.P., de Kruif M.D., *et al.* 2006. Changing Epidemiology of Dengue Haemorrhagic Fever in Indonesia. *Dengue Bull.* (30): 1-14.
- Shrestha, B., Brien, J. D., Sukopolvi-Petty, S., *et al.* 2010. The Development of Therapeutic Antibodies that Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1. *PLoS Pathogens*. 6(4): e1000823.

- Simmons, M., Burgess, T., Lynch, J., *et al.* 2010. Protection Against Dengue Virus by Non-replicating and Live Attenuated Vaccines Used Together in a Prime Boost Vaccination Strategy. *Virology*. 396(2): 280-288.
- Suhendro, Nainggolan, L., Chen, K., *et al.* 2006. Demam Berdarah Dengue. *Buku Ajar Ilmu Penyakit Dalam*. Jilid III. Edisi IV. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. pp. 1731-1735.
- Suyitno, H. 2011. Jenis Vaksin. *Pedoman Imunisasi di Indonesia*. Edisi 4. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia. pp. 134-139.
- Suzuki, R., Winkelmann, E. R., & Mason, P. W. (2009). Construction and Characterization of a Single-cycle Chimeric Flavivirus Vaccine Candidate that Protects Mice Against Lethal Challenge with Dengue Virus Type 2. *Journal of Virology*. 83(4): 1870-1880.
- Triyanto, I. 2007. Konsep Imunisasi Halalan Thoyyiban. <http://www.halalguide.info/content/view/802/38/>. Diakses tanggal 24 Februari 2017.
- Tsai J.J., Chan K.S., Chang J.S., *et al.* 2009. Effect of Serotypes on Clinical Manifestations of Dengue Fever in Adults. *J Microbiol Immunol Infect*. 42(6): 471-478.
- Tuasikal, MA. 2010. Masih Ada yang Meragukan Haramnya Anjing. <https://rumaysho.com/963-masih-ada-yang-meragukan-haramnya-anjing-2.html>. Diakses tanggal 25 Februari 2017.
- Uddin, J., Akbar, A., & Djamil, A. 2002. Islam dan Kesehatan. *Disiplin Ilmu Kedokteran dan Kesehatan I Buku Daras Pendidikan Agama Islam pada Perguruan Tinggi Umum Jurusan Kedokteran dan Kesehatan*. Jakarta: Departemen Agama RI. pp 10-11.
- Villar, L., Dayan, G. H., Arredondo-García, J. L., *et al.* 2015. Efficacy of a Tetravalent Dengue Vaccine in Children in Latin America. *New England Journal of Medicine*. 372(2): 113-123.
- WHO. 2009. *Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. New Edition*. Geneva: World Health Organization. pp 59-86.

- WHO. 2012. *Global Strategy for Dengue Prevention and Control, 2012–2020*. Geneva: World Health Organization. pp 3-28.
- WHO. 2014. *Policy Statement: Multi-dose Vial Policy (MDVP)*. Revision 2014. Geneva: World Health Organization. pp 4-6.
- WHO. 2016. *Background Paper on Dengue Vaccines*. Geneva: World Health Organization. pp 18-36.
- WHO, 2017. *Module 2: Types of Vaccine and Adverse Reaction*. Geneva: World Health Organization. pp 2-10.
- Widoyono. 2008. *Penyakit Tropis, Epidemiologi, Penularan, Pencegahan dan Pemberantasannya*. Jakarta : Erlangga. pp 27-34.
- Wright, P. F., Durbin, A. P., Whitehead, S. S., *et al.* 2009. Phase 1 Trial of the Dengue Virus Type 4 Vaccine Candidate rDEN4Δ30-4995 in Healthy Adult Volunteers. *The American Journal of Tropical Medicine and Hygiene*. 81(5): 834-841.
- Yang J, Zhang J, Chen W, *et al.* 2012. Eliciting Cross-neutralizing Antibodies in Mice Challenged with a Dengue Virus Envelope Domain III Expressed in *Escherichia coli*. *Can J Microbiol*. 58(4): 369-380.
- Zuhroni, Riani, N., & Nazaruddin, N. 2003. *Islam untuk Disiplin Kesehatan dan Kedokteran 2 (Fiqh Kontemporer)*. Jakarta: Departemen Agama RI. pp 144-149.
- Zuhroni. 2012. *Hukum Islam terhadap Berbagai Masalah Kedokteran dan Kesehatan Kontemporer*. Jakarta: Bagian Agama Universitas YARSI. pp 3-8.